Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan versus standard care in children with pulmonary arterial hypertension
MOH_2017-03-14_000228Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Time to disease progression. Started Feb 2017; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-03-14_000228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000228.